Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PMM2 | O15305 | 1/20 | 0.30 |
| ▸ | MPI | P34949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521831 | 0.88 | MAPT (0.46) | MAPTLMNAGAAALDH1A1FGFR2 | |
| SCHEMBL1521551 | 0.86 | FGFR1 (0.32) | MAPTFGFR2FGFR4FGFR3FGFR1 | |
| SCHEMBL1521496 | 0.72 | MAPT (0.42) | MAPTLMNAGAAFGFR2FGFR4 | |
| SCHEMBL1521643 | 0.72 | FGFR1 (0.39) | MAPTLMNAALDH1A1FGFR2FGFR4 | |
| SCHEMBL1521547 | 0.72 | RPS6KA3 (0.32) | FGFR2FGFR4FGFR3FGFR1 | |
| SCHEMBL1521677 | 0.72 | FGFR1 (0.38) | FGFR2FGFR4FGFR3FGFR1BACE1 | |
| SCHEMBL1521737 | 0.70 | FGFR1 (0.43) | MAPTFGFR2FGFR4FGFR3FGFR1 | |
| SCHEMBL1521913 | 0.70 | FGFR4 (0.60) | MAPTLMNAGAAFGFR2FGFR4 | |
| SCHEMBL1521883 | 0.68 | FGFR4 (0.46) | MAPTLMNAGAAFGFR2FGFR4 | |
| SCHEMBL18642219 | 0.68 | MAPT (0.50) | MAPTLMNAGAAALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | disclosed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2063896-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008033999-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | BRAF, PRKDC, RAF1 | MAPT 1608/4885LMNA 3483/4885GAA 4704/4885 |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | MAPT 1608/4885LMNA 3483/4885GAA 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.